Genmab has shared the first data on rinatabart sesutecan (Rina-S) in advanced endome | Genmab has shared the first data on ...

In this video, Ursula A. Matulonis, MD, discusses results from the phase 3 MIRASOL trial of mirvetuximab soravtansine-gynx for patients with folate receptor alpha-positive, platinum-resistant ovarian ...

AbbVie's Elahere has been shown to reduce the risk of death in patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer by a third, reinforcing its blockbuster ...

ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

This could upend an already shaky stock market. The recent market downturn is an excellent example. After the election, the ...

A major driver of this success was the positive outcome of the MIRASOL trial, where Elahere showed a clear advantage over chemotherapy in treating ovarian cancer, cutting the risk of death by 32% ...

AbbVie’s oncology/hematology sales rose 7.5% to $1.63 billion in the quarter, as sales from the recently acquired ovarian cancer drug Elahere and rising Venclexta sales more than offset the ...

Advanced ovarian cancer patients may also turn to a type of antibody-drug conjugate called Elahere (molecular name mirvetuximab soravtansine) that has been shown to help patients live longer without ...

Medscape Medical News, October 11, 2024 Alert EMA Backs Approval of Elahere for Ovarian Cancer Elahere was found to improve survival in patients with FR-alpha–positive, platinum-resistant ...